As doxorubicin is a chemotherapy that is known to target highly proliferative cells and typically used to treat TNBCs (TNBC cells are more sensitive to doxorubicin treatment and have faster cell cycle progression due to their more aggressive nature as compared with luminal cancer cells) in clinics, silencing SNRPD1 would dampen its anti-cancer efficacy if SNRPD1 over-expression was associated with enhanced cell cycle progression. The gene discussed is SNRPD1; the disease is cancer.